Site-dependent differences in both prelamin A and adipogenic genes in subcutaneous adipose tissue of patients with type 2 familial partial lipodystrophy

Journal of Medical Genetics

Volumn 46, Issue 1, 2009, Pages 40-48

  Araújo Vilar, David ^a   Lattanzi, G ^b   Gonzalez Mendez B ^a   Costa Freitas, A T ^a   Prieto, D ^c   Columbaro, M ^b   Mattioli, E ^b   Victoria, B ^a   Martinez Sanchez N ^a   Ramazanova, A ^a   Fraga, M ^d   Beiras, A ^d   Forteza, J ^d   Dominguez Gerpe L ^a   Calvo, C ^c   Lado Abeal, J ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b CNR   (Italy)

^c Instituto de Salud Carlos III   (Spain)

^d UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D3; INSULIN; LAMIN A; LIPOPROTEIN LIPASE; NUCLEAR PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PRELAMIN A; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ABDOMINAL FAT; ADIPOCYTE; ADIPOGENESIS; ADULT; ARTICLE; CELL DIFFERENTIATION; CELL NUCLEUS; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTRON MICROSCOPY; FAMILIAL PARTIAL LIPODYSTROPHY; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; HETEROCHROMATIN; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; INSULIN SENSITIVITY; MALE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN BIOPSY; SUBCUTANEOUS FAT; TISSUE REGENERATION; WESTERN BLOTTING;

ADIPOGENESIS; ADIPOSE TISSUE; ADULT; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENES, REGULATOR; HUMANS; LAMIN TYPE A; LIPODYSTROPHY, FAMILIAL PARTIAL; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PROTEIN PRECURSORS; SUBCUTANEOUS FAT;

EID: 58549098066     PISSN: 00222593     EISSN: 14686244     Source Type: Journal    
DOI: 10.1136/jmg.2008.059485     Document Type: Article

References (54)

1. Cao H, Hegele RA. Nuclear lamin A/C R4820 mutation in Canadian kindreds with Dunnigan-type familial partial lipodystrophy. Hum Mol Genet 2000;9:109-12.
2. Rusiñol AE, Sinensky MS. Farnesylated lamins, progeroid syndromes and farnesyl transferase inhibitors. J Cell Sci 2006; 15:3265-72.
3. Parnaik VK, Manju K. Laminopathies: Multiple disorders arising from defects in nuclear architecture. J Biosci 2006; 31:405-21.
4. Lammerding J, Schulze PC, Takahashi T, Kozlov S, Sullivan T, Kamm RD, Stewart CL, Lee RT. Lamin A/C deficiency causes defective nuclear mechanics and mechanotransduction. J Clin Invest 2004; 113:370-8.
5. Mancini MA, Shan B, Nickerson JA, Penman S, Lee WH. The retinoblastoma gene product is a cell cycle-dependent, nuclear matrix-associated protein. Proc Natl Acad Sci U S A 1994; 91:418-22.
6. Lloyd DJ, Trembath RC, S. Shackleton S. A novel interaction between lamin A and SREBP1: implications for partial lipodystrophy and other laminopathies. Hum Mol Genet 2002;11:769-77.
7. Caron M., Auclair M, Sterlingot H, Komprobst M, Capeau, J. Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation. AIDS 2003;17:2437-44.
8. Garg A. Acquired and Inherited Lipodystrophies. N Engl J Med 2004;350:1220-34.
9. Vidal-Puig AJ, Considine RV, Jimenez-Linan M, Werman A, Pories M, Caro JF, Flier JS. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss andregulation by insulin and glucocorticoids. J Clin Invest 1997;99:2416-22.
10. Capanni C, Mattioli E, Columbaro M, Lucarelli E, Parnaik VK, Novelli G, Wehnert M, Cenni V, Maraldi NM, Squarzoni S, Lattanzi G. Altered pre-lamin A processing is a common mechanism leading to lipodystrophy. Hum Mol Genet 2005;14:1489-502.
11. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPARgamma2, a lipid-activated transcription factor. Cell 1994;79:1147-56.
12. Fajas L, Jean-Charles Fruchart JC, Auwerx J. Transcriptional control of adipogenesis. Curr Opin Cell Biol 1998; 10:165-73.
13. Miles PD, Barak Y, He W, Evans RIM, Olefsky JM. Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. J Clin Invest 2000;105:287-92.
14. Boguslavsky RL, Colin L. Stewart CL, Worman HJ. Nuclear lamin A inhibits adipocyte differentiation: implications for Dunnigan-type familial partial lipodystrophy. Hum Mol Genet 2006; 15:653-63.
15. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002;109:1125-31.
16. Fajas L, Schoonjans K, Gelman L, Kim JB, Najib J, Martin G, Fruchart JC, Briggs M, Spiegelman BM, Auwerx J. Regulation of PPARγ expression by ADD-1/SREBP-1: implications for adipocyte differentiation and metabolism. Mol Cell Biol 1999;19:5495503.
17. Hegele RA. Molecular basis of partial lipodystrophy and prospects for therapy. Trends Mol Med 1999;7:121-6.
18. Nikolova V, Leimena C, McMahon AC, Tan JC, Chandar S, Jogia D, Kesteven SH, Michalicek J, Otway R, Verheyen F, Rainer S, Stewart CL, Martin D, Feneley MP, Fatkin D. Defects in nuclear structure and function promote dilated cardiomyopathy in lamin A/C deficient mice. J Clin Invest 2004;113:357-69.
19. Hübner S, Eam JE, Hübner A, Jans DA. Laminopathy-inducing lamin A mutants can induce redistribution of lamin binding proteins into nuclear aggregates. Exp Cell Res 2006; 312:171-83.
20. Chen PL, Riley DJ, Chen Y, Lee WH Retinoblastoma protein positively regulates terminal adipocyte differentiation through direct interaction with C/EBPs. Genes Dev 1996;10:2794-04.
21. Markiewicz E, Dechat T, Foisner R, Quinlan RA, Hutchison CJ. Lamin A/C binding protein LAP2alpha is required for nuclear anchorage of retinoblastoma protein. Mol Biol Cell 2002;13:4401-13.
22. Pekovic V, Harborth J, Broers JL, Ramaekers FC, van Engelen B, Lammens M, von Zglinicki T, Foisner R, Hutchison C, Markiewicz E. Nucleoplasmic LAP2alpha-lamin A complexes are required to maintain a proliferative state in human fibroblasts. J Cell Biol 2007; 15:163-72.
23. Gu W, Schneider JW, Condorelli G, Kaushal S, Mahdavi V, Nadal-Ginard B. Interaction of myogenic factors and the retinoblastoma protein mediates muscle cell commitment and differentiation. Cell 1993;72:309-24.
24. Mariappan I, Gurung R,Thanumalayan S, Parnaik VK. Identification of cyclin D3 as a new interaction partner of lamin A/C. Biochem Biophys Res Commun 2007;355:981-985.
25. Bartkova J, Lukas J, Strauss M, Bartek M. Cyclin D3: requirement for G1/S transition and high abundance in quiescent tissues suggest a dual role in proliferation and differentiation. Oncogene 1998; 17:1027-37.
26. Sarruf DA, Iankova I, Abella A, Assou S, Miard S, Fajas L. Cyclin D3 promotes adipogenesis through activation of peroxisome proliferator-activated receptor γ. Mole Cell Biol 2005; 25:9985-95.
27. Araújo-Vilar D, Loidi L, Domínguez F, Cabezas-Cerrato J. Phenotypic gender differences in subjects with familial partial lipodystrophy (Dunnigan variety) due to a nuclear lamin A/C R482W mutation. Horm Metab Res 2003;35:29-35.
28. Araújo-Vilar D, Rega-Liste CA, Garcia-Estevez DA, Sarmiento-Escalona F, Mosquera-Tallon V, Cabezas-Cerrato J. Minimal model of glucose metabolism: modified equations and its application in the study of insulin sensitivity in obese subjects. Diabetes Res Clin Pract 1998;39:129-41.
29. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985;28:412-19.
30. -ΔΔCT method. Methods 2001;25:402-8.
31. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000; 21:697-738.
32. Lelliott CJ, Logie L, Sewter CR Berger D, Iani P, Blows F, O'Rahilly S, Vidal-Puig A. Lamin expression in human adipose cells in relation to anatomical site and differentiation state. J Clin Endocrinol Metab 2002;87:728-34.
33. Caron M, Auclair M, Donadille B, Béréziat V, Guerci B, Laville M, Narbonne H, Bodemer C, Lascols O, Capeau J, Vigouroux C. Human lipodystrophies linked to mutations in A-type lamins and to HIV protease inhibitor therapy are both associated with prelamin A accumulation, oxidative stress and premature cellular senescence. Cell Death Differ 2007;14:1759-67.
34. Mattioli E, Columbaro M, Capanni C, Santi S, Maraldi NM, D'Apice MR, Novelli G, Fiddle M, Squarzoni S, Foisner R, Lattanzi G. Drugs affecting prelamin A processing: Effects on heterochromatin organization. Exp Cell Res 2007;314:453-62.
35. Maraldi NM, Capanni C, Lattanzi G, Camozzi D, Facchini A, Manzoli FA. SREBP1 interaction with prelamin A forms: A pathogenic mechanism for lipodystrophic laminopathies. Adv Enzyme Regul 2008; 48:209-23.
36. Capanni C, Cenni V, Mattioli E, Sabatelli P, Ognibene A, Columbaro M, Parnaik VK, Wehnert M, Maraldi NM, Squarzoni S, Lattanzi G. Failure of lamin A/C to functionally assemble in R482L mutated familial partial lipodystrophy fibroblasts: altered intermolecular interaction with emerin and implications for gene transcription. Exp Cell Res 2003;291:122-34.
37. Ren D, Collingwood TN, Rebar EJ, Wolffe AP, Camp S. PPARγ knockdown by engineered transcription factors: exogenous PPARγ2 but not PPARγ1 reactivates adipogenesis. Genes Dev 2002; 16:27-32.
38. Freedman BD, Lee EJ, Park Y, Jameson JL. A dominant negative peroxisome proliferators-activated receptor-7 knock-in mouse exhibits features of the metabolic syndrome. J Biol Chem 2005; 280:17118-125.
39. Agarwal AK, Garg A. A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy. J Clin Endocrinol Metab 2002; 87:408-11.
40. Frolov MV, Dyson NJ. Molecular mechanisms of E2F-dependent activation and pRB-mediated repression. J Cell Sci 2004; 117:2173-81.
41. Fajas L., Egler V, Reiter R, Hansen J, Kristiansen K, Miard S, Auwerx J. The retinoblastoma-histone deacetylase 3 complex inhibits the peroxisome proliferator-activated receptor gamma and adipocyte differentiation. Dev Cell 2002;3:903-10.
42. Richon V, Lyle RE, McGehee REJ. Regulation and expression of retinoblastoma proteins p107 and p130 during 3T3-L1 adipocyte differentiation. J BiolChem 1997;272:10117-24.
43. Higgins C, Chatterjee S, Cherington V. The block of adipocyte differentiation by a C-terminally truncated, but not by full-length, simian virus 40 large tumor antigen is dependent on an intact retinoblastoma susceptibility protein family binding domain. J Virol 1996;70:745-52.
44. Johnson BR, Nitta RT, Frock RL, Mounkes L, Barbie DA, Stewart CL, Harlow E, Kennedy BK. A-type lamins regulate retinoblastoma protein function by promoting subnuclear localization and preventing proteasomal degradation. Proc Natl Acad Sci U S A 2004;101:9677-82.
45. Nitta RT, Jameson SA, Kudlow BA, Conlan LA, Kennedy BK. Stabilization of the retinoblastoma protein by A-type nuclear lamins is required for INK4A-mediated cell cycle arrest. Mol Cell Biol 2006;26:5360-72.
46. Wang C, Pattabiraman N, Zhou JN, Fu M, Sakamaki T, Albanese C, Li Z, Wu K, Hulit J, Neumeister P, Novikoff PM, Brownlee M, Scherer PhE, Jones JIG, Whitney KD, Donehower LA, Harris EL, Rohan T, Johns DC, Pestell RG. Cyclin D1 Repression of Peroxisome proliferator-activarted receptor γ. Expression and transactivation. Mol Cell Biol 2003; 23:6159-73.
47. Gotzmann J, Foisner R. A-type lamin complexes and regenerative potential: a step towards understanding laminopathic diseases? Histochem Cell Biol 2006;125:33-41.
48. Espada J, Varela I, Flores I, Ugalde AP, Cadiñanos J, Pendás AM, Stewart CL, Tryggvason K, Blasco MA, Freije JM, López-Otín C. Nuclear envelope defects cause stem cell dysfunction in premature-aging mice. J Cell Biol 2008; 181:27-35.
49. Scaffidi P, Misteli T. Lamin A-dependent misregulation of adult stem cells associated with accelerated ageing. Nat Cell Biol 2008;10:452-9.
50. Lattanzi G, Ognibene A, Sabatelli P, Capanni C, Toniolo D, Columbaro M, Santi S, Riccio M, Merlini L, Maraldi NM, Squarzoni S. Emerin expression at the early stages of myogenic differentiation. Differentiation 2000;66:208-17.
51. Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM, Perry JR, Elliott KS, Lange H, Rayner NW, Shields B, Harries LW, Barrett JC, Ellard S, Groves CJ, Knight B, Patch AM, Ness AR, Ebrahim S, Lawlor DA, Ring SM, Ben-Shlomo Y, Jarvelin MR, Sovio U, Bennett AJ, Melzer D, Ferrucci L, Loos R., Barroso I, Wareham NJ, Karpe F, Owen KR, Carden LR, Walker M, Hitman GA, Palmer CN, Doney AS, Morris AD, Smith GD, Hattersley AT, McCarthy MI. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 2007;316:889-94.
52. Klöting N, Schleinitz D, Ruschke K, Berndt J, Fasshauer M, Tönjes A, Schön MR, Kovacs P, Stumvoll M, Blüher M. Inverse relationship between obesity and FTO gene expression in visceral adipose tissue in humans. Diabetologia 2008;51:641-7.
53. Yang X, Enerbäck S, Smith U. Reduced expression of FOXC2 and brown adipogenic genes in human subjects with insulin resistance. Obes Res 2003;11:1182-91.
54. Dubois SG, Heilbronn LK, Smith SR, Allbu JB, Kelley DE, Ravussin E and the Look AHEAD Adipose Research Group. Decreased expression of adipogene genes in obese subjects with type 2 diabetes. Obesity 2006;14:1543-52.